regenerative medicine

With the sequencing of the flatworm Macrostomum lignano, Cold Spring Harbor Laboratory researchers hope to provide a resource for regeneration studies.

NEW YORK (GenomeWeb News) – The Centre for Commercialization of Regenerative Medicine and Nikon has reached a deal aimed at high-throughput studies of how stem cells respond to test molecules.

The worldwide distribution agreement covers lentiviral vector technologies for induced pluripotent stem cells.

The Center for Stem Cell and Regenerative Medicine, which comprises researchers from Ohio academic institutions, research hospitals, and the private sector, will use the grant to fund nine new research projects this year and at least eight in coming years.

Tech Transfer Tidbits

Premium

Pfizer and UCL to develop stem-cell therapies for AMD; Clarient licenses breast cancer biomarkers from Indiana U; Nanosys and Harvard to outlicense nanowire IP; Luminex settles with SUNY and U of Illinois, and more …

Although iZumi does not have a license to Kyoto iPSC patents, the collaboration builds upon other seminal iPSC IP it recently licensed from Bayer. The Kyoto deal may also help the company better define iZumi's stake in what is shaping up to be a complicated IP landscape surrounding the technology.

Around the Regions

Premium

Maryland Biotechnology Investment Incentive Tax Credit, Maryland Stem Cell Research Fund, Washington State Life Sciences Discovery Fund, California Institute for Regenerative Medicine, Sanford Consortium for Regenerative Medicine, Missouri Life-Sci/Tech Tax Credits, Wisconsin Technology Venture Fund, New Jersey Edison Innovation Fund, University City Science Center QED

The deal is Salk's second broad-based research pact with a drug maker in as many years: In early 2008 the non-profit biological research institute signed a similar deal in the area of inflammation with French specialty pharma Ipsen.

Tech Transfer Tidbits

Premium

Merck Serono launches venture fund; UK's MedCell and Manchester U partner on stem cell manufacturing; VGX Pharma to study DNA vaccine tech with PATH, UPenn; and more …

Pages

The president of France's National Research Agency has resigned, according to Nature News.

A senator wants a "right-to-try" provision in the US Food and Drug Administration funding bill, but an ethicist says at Stat News that it would undermine the role of clinical trials.

In PNAS this week: red algae Porphyra umbicalis genome, deep neural network model for sequencing peptides, and more.

The Guardian's Barbara Ellen has tried out some DNA testing services to see whether they provide valuable information.